KPTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KPTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Karyopharm Therapeutics has the Momentum Rank of 2.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Karyopharm Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Momentum Rank falls into.
Thank you for viewing the detailed overview of Karyopharm Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard A. Paulson | director, officer: President and CEO | 85 WELLS AVENUE, NEWTON MA 02459 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Michael Mason | officer: EVP, CFO, Treasurer | 300 3RD STREET, CAMBRIDGE MA 02142 |
Michael Mano | officer: SVP, General Counsel&Secretary | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Sohanya Roshan Cheng | officer: SVP Sales & Commercial Ops | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Zhen Su | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Stuart Poulton | officer: EVP, Chief Development Officer | 85 WELLS AVENUE, NEWTON MA 02459 |
Reshma Rangwala | officer: EVP & Chief Medical Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Stephen Mitchener | officer: SVP, Chief Business Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Ran Frenkel | officer: EVP, WW Development Operations | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459 |
Jatin Shah | officer: EVP, Chief Medical Officer | C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Sharon Shacham | officer: C.S.O & Pres. of Res & Develop | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael Kauffman | director, officer: President, C.E.O., C.M.O. | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
From GuruFocus
By PRNewswire • 01-03-2024
By PRNewswire PRNewswire • 04-14-2023
By PRNewswire • 09-05-2023
By PRNewswire • 09-01-2023
By PRNewswire • 11-14-2023
By PRNewswire • 08-01-2023
By PRNewswire • 10-26-2023
By PRNewswire PRNewswire • 05-01-2023
By PRNewswire PRNewswire • 05-04-2023
By PRNewswire PRNewswire • 06-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.